The methods for the culture and cardiomyocyte differentiation of human embryonic stem
cells, and later human induced pluripotent stem cells (hiPSC), have moved from a complex …

Despite numerous advances in treatments for cardiovascular disease, heart failure (HF)
remains the leading cause of death worldwide. A significant factor contributing to the …

Small‐interfering RNA (siRNA) therapy is considered a powerful therapeutic strategy for
treating cardiac hypertrophy, an important risk factor for subsequent cardiac morbidity and …

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have wide
potential application in basic research, drug discovery, and regenerative medicine, but …

In vitro modelling the complex (patho‐) physiological conditions of the heart is a major
challenge in cardiovascular research. In recent years, methods based on three‐dimensional …

In recent years, nucleic acid-based therapeutics have gained increasing importance as
novel treatment options for disease prevention and treatment. Synthetic messenger RNAs …

Cardiovascular diseases persist as a global health challenge that requires methodological
innovation for effective drug development. Conventional pipelines relying on animal models …

Pathogenic variants in MYH7 and MYBPC3 account for the majority of hypertrophic
cardiomyopathy (HCM). Targeted drugs like myosin ATPase inhibitors have not been …

Cardiovascular diseases are the leading cause of death worldwide. Several strategies–
small molecules, gene therapy, surgeries, cardiac rehabilitation–have been developed to …

Developmental research has attempted to untangle the exact signals that control heart
growth and size, with knockout studies in mice identifying pivotal roles for Wnt and Hippo …